Re 20
Re 20 is a proton pump inhibitor used to treat gastric and duodenal ulcers, gastro-oesophageal reflux disease, and dyspepsia. It works by reducing gastric acid secretion. Common side effects include gastrointestinal disturbances and headache. Long-term use may increase the risk of fractures and magnesium deficiency. It is typically administered orally or intravenously for severe conditions.
Re 40
Re 40 is a proton pump inhibitor used to treat gastric and duodenal ulcers, gastro-oesophageal reflux disease, and dyspepsia. It works by reducing gastric acid secretion. Common side effects include gastrointestinal disturbances and headache. Long-term use may increase the risk of fractures and magnesium deficiency. It is typically administered orally or intravenously for severe conditions.
Regerd 20 mg
Regerd 20 mg is a proton pump inhibitor used to treat gastric and duodenal ulcers, gastro-oesophageal reflux disease, and dyspepsia. It works by reducing gastric acid secretion. Common side effects include gastrointestinal disturbances and headache. Long-term use may increase the risk of fractures and magnesium deficiency. It is typically administered orally or intravenously for severe conditions.
Regerd 40 mg
Regerd 40 mg is a proton pump inhibitor used to treat gastric and duodenal ulcers, gastro-oesophageal reflux disease, and dyspepsia. It works by reducing gastric acid secretion. Common side effects include gastrointestinal disturbances and headache. Long-term use may increase the risk of fractures and magnesium deficiency. It is typically administered orally or intravenously for severe conditions.
Regerd Injection
Regerd Injection is a proton pump inhibitor used to treat gastric and duodenal ulcers, gastro-oesophageal reflux disease, and dyspepsia. It works by reducing gastric acid secretion. Common side effects include gastrointestinal disturbances and headache. Long-term use may increase the risk of fractures and magnesium deficiency. It is typically administered orally or intravenously for severe conditions.
